^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) + GMI-1359 (CXCR4 antagonist, E-selectin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 6038: Combined targeting of E-selectin/CXCR4 and FLT3 by GMI-1359 and sorafenib effectively reduces leukemia cell burden and protects normal hematopoiesis in a patient-derived AML xenograft model
Published date:
06/23/2020
Excerpt:
We then evaluated anti-leukemia effects of co-targeting E-selectin/CXCR4 and FLT3 with GMI-1359 and sorafenib in a patient-derived AML xenograft model (harboring FLT3-ITD and WT1 mutations)...The GMI-1359/sorafenib combination improved mouse survival (median survival were 109, 87, 126 and 138.5 days for the vehicle, GMI-1359, sorafenib and combination groups, respectively).
DOI:
10.1158/1538-7445.AM2020-6038
